OpenAlex
PricingAboutJobs
Log inGet started
Work

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

HTML

Year: 2019
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2019-125356
Authors: Michal Ariela Raz, Jon E. Arnason, Osnat Bairey, Lev Shvidel, Ariel Aviv, Sharon Ben Baruch, Chava Perry, Nadav Sarid, David Varon, Ilya Kirgner, Yair Herishanu, Irit Avivi
Institutions: Tel Aviv Sourasky Medical Center, Beth Israel Deaconess Medical Center, Tel Aviv University, Rabin Medical Center, Hebrew University of Jerusalem, Kaplan Medical Center, Technion – Israel Institute of Technology, Emek Medical Center
Language: English

Topic: Chronic Lymphocytic Leukemia Research
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: ibrutinib, direct oral anticoagulants, major bleeding, bleeding risk, B-cell lymphoproliferative disorders, chronic lymphocytic leukemia, mantle cell lymphoma, apixaban, rivaroxaban, dabigatran, platelet dysfunction, BTK inhibitors, drug-drug interactions, atrial fibrillation, venous thromboembolism
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2989170640
Cites:
Cited by: 3
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security